MIMEDX Announces Launch of CHORIOFIX™

Rhea-AI Summary

MiMedx (Nasdaq: MDXG) announced the commercial launch of CHORIOFIX on March 23, 2026, a lyophilized placental allograft composed of two chorion layers with an intact intermediate layer.

The company said CHORIOFIX is its thickest product to date, designed to improve handling, positioning and suturing, and has been added to the prospective randomized CAMPAIGN trial to evaluate performance versus standard of care in non-healing diabetic foot ulcers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Positive

• Commercial launch of CHORIOFIX expands AWC product portfolio
• CHORIOFIX added to prospective randomized CAMPAIGN trial
• Product design: two chorion layers plus intermediate layer (thickest product)

Negative

• Clinical support limited to early access anecdotal observations—no trial outcomes disclosed
• No financial guidance or sales projections tied to the CHORIOFIX launch

News Market Reaction – MDXG

+2.91%

1 alert

+2.91% News Effect

+$18M Valuation Impact

$640.32M Market Cap

0.0x Rel. Volume

On the day this news was published, MDXG gained 2.91%, reflecting a moderate positive market reaction. This price movement added approximately $18M to the company's valuation, bringing the market cap to $640.32M at that time.

Data tracked by StockTitan Argus on the day of publication.

What This Means

This announcement highlights MIMEDX’s continued expansion of its advanced wound care portfolio throu...

Analysis

This announcement highlights MIMEDX’s continued expansion of its advanced wound care portfolio through CHORIOFIX, a thicker, lyophilized placental allograft now included in the CAMPAIGN randomized controlled trial against standard of care for diabetic foot ulcers. In recent months, the company has paired product launches and distribution deals with record 2025 results. Investors may watch for clinical readouts from CAMPAIGN, adoption trends for CHORIOFIX, and how these developments interact with the company’s broader placental allograft franchise.

Historical Context

5 past events · Latest: Mar 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 05	Product launch	Positive	-1.4%	Launch of AMNIOFIX Thyroid Shields for endocrine surgery protection.
Feb 25	Earnings results	Positive	-1.3%	Record Q4 and full-year 2025 net sales and profitability metrics.
Feb 17	Earnings call notice	Positive	+0.8%	Announcement of date and time for Q4 and full-year 2025 call.
Feb 04	Distribution deal	Positive	+2.8%	Exclusive distribution agreement for three 510(k)-cleared wound products.
Feb 02	Product milestone	Positive	-0.4%	15-year anniversary of EPIFIX and AMNIOFIX placental allografts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive product and corporate updates have often seen muted or slightly negative next-day reactions, with occasional upside on distribution news.

Recent Company History

Over the last several months, MIMEDX has focused on expanding and highlighting its wound and surgical product portfolio. On Feb 2, 2026, it marked the 15-year anniversary of EPIFIX and AMNIOFIX, followed by a new exclusive distribution agreement for Hydrelix, NovaForm, and G4Derm Plus on Feb 4, which coincided with a +2.82% move. Record 2025 financial results on Feb 25 and the AMNIOFIX Thyroid Shields launch on Mar 5 both saw modest negative price reactions, suggesting that even strong or innovative news has not consistently driven upside.

Regulatory & Risk Context

Short Interest: 6.44%

Short Interest

6.44% of float

0% 15% 30%+

low as of 2026-05-29 Days to cover: 5.12

Key Terms

advanced wound care, placental allografts, randomized controlled trial, standard of care, +3 more

7 terms

advanced wound care medical

"Further Expands Company’s Broad Portfolio of Advanced Wound Care (“AWC”) Products"

Specialized products and treatments used to heal hard-to-close or long-lasting wounds, such as advanced dressings, engineered tissue patches and devices that control infection and support tissue repair. For investors, advanced wound care matters because it is a higher-value, fast-evolving segment where clinical results, regulatory clearance and insurance reimbursement drive sales, margins and recurring revenue—similar to a specialized toolkit that can replace basic care and reduce overall healthcare costs.

placental allografts medical

"latest advanced wound care innovation in its product portfolio of placental allografts"

Human placental allografts are biological products made from donated placenta tissue that has been processed for use in medical treatments, typically to promote wound healing and tissue repair. Think of them as natural, sterile bandages or scaffolds that help the body rebuild damaged tissue; investors watch them because clinical results, regulatory approvals, manufacturing scale, and reimbursement decisions directly affect the commercial potential and risk profile of companies developing and selling these therapies.

randomized controlled trial medical

"CAMPAIGN trial, a prospective randomized controlled trial (“RCT”) designed to evaluate"

A randomized controlled trial is a research method that tests the effects of a new idea or treatment by randomly dividing participants into two groups: one that receives the treatment and one that does not. This approach helps ensure that the results are fair and unbiased, providing clear evidence about whether the treatment actually works. Investors value such trials because they offer reliable information that can influence decision-making and reduce uncertainty.

standard of care medical

"evaluate the performance of EPIEFFECT and now CHORIOFIX against standard of care (“SOC”)"

Standard of care is the accepted medical treatment or clinical approach that most qualified doctors would use for a given condition today, based on available evidence, guidelines and common practice. For investors, it acts like the baseline product customers expect: a new therapy or device must match or improve on the standard of care to win market share, gain reimbursement and limit legal or regulatory risk.

diabetic foot ulcers medical

"in the treatment of non-healing diabetic foot ulcers (“DFUs”)"

A diabetic foot ulcer is an open sore or wound on the foot that occurs when high blood sugar and nerve damage prevent normal healing, much like a small pothole that keeps widening because the road can’t be properly repaired. It matters to investors because these wounds drive demand for treatments, medical devices, wound-care drugs and hospital services, and they carry risks of infection and amputation that can shape healthcare costs, reimbursement decisions and clinical trial opportunities.

lyophilized medical

"CHORIOFIX is a lyophilized human placental allograft"

Lyophilized means a drug, vaccine, or biological product has been freeze-dried: water is removed by freezing the item and then turning the ice into vapor to leave a dry, stable powder. For investors, lyophilization matters because it improves shelf life, eases shipping and storage without refrigeration, and can affect manufacturing cost, regulatory approval paths, and commercial reach—much like how freeze-dried coffee or fruit lasts longer and travels better than fresh.

allograft medical

"CHORIOFIX is a lyophilized human placental allograft that includes two layers"

Tissue taken from one person and transplanted into another to repair or replace damaged body parts, such as bone, skin, or heart valves. For investors, allografts matter because their use involves manufacturing standards, supply and safety controls, regulatory approvals, and reimbursement rules that can affect sales, liability and growth for companies that process, store or sell these biological materials — similar to how sourcing and quality control of key parts affect a manufacturer’s business.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Further Expands Company’s Broad Portfolio of Advanced Wound Care (“AWC”) Products

MARIETTA, Ga., March 23, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of CHORIOFIX™, the latest advanced wound care innovation in its product portfolio of placental allografts.

“CHORIOFIX is an organically developed product, created based on our deep understanding of the scientific and clinical attributes of the chorion layer,” stated Michelle Massee, MIMEDX VP, Research & Development. “It consists of two chorion layers with an intact intermediate layer, making it our thickest product to date. The allograft’s structure enhances handling, particularly during positioning and suturing, while its uniform, dual-sided chorion configuration eliminates the need for orientation during application.”

“I have used several MIMEDX products for complex lower extremity wound care in the hospital setting,” added Andrew Horine, DO, Family Medicine Physician at Carroll County Memorial Hospital.   “In an early access evaluation of CHORIOFIX, I was impressed with the product’s handling characteristics and the effective wound closure observed anecdotally in my patients. The naturally thicker composition is well-suited for use in large deficits and deep, tunneling wounds, which represent some of the most difficult wound types to treat effectively.”

Continuing its commitment to generate best-in-class scientific and clinical data, the Company has also added CHORIOFIX to its CAMPAIGN trial, a prospective randomized controlled trial (“RCT”) designed to evaluate the performance of EPIEFFECT and now CHORIOFIX against standard of care (“SOC”) in the treatment of non-healing diabetic foot ulcers (“DFUs”).  

CHORIOFIX is a lyophilized human placental allograft that includes two layers of chorion with attached intermediate layer. CHORIOFIX is intended for use as a barrier to provide a protective environment in acute and chronic wounds.

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com

FAQ

What is CHORIOFIX launched by MiMedx (MDXG) on March 23, 2026?

CHORIOFIX is a lyophilized human placental allograft composed of two chorion layers and an intermediate layer. According to the company, it is the thickest product in its portfolio and intended as a protective barrier for acute and chronic wounds.

How does CHORIOFIX differ from other MiMedx products (MDXG)?

CHORIOFIX features a uniform, dual-sided chorion configuration with an intact intermediate layer for thicker structure. According to the company, this design improves handling, positioning and suturing and eliminates orientation during application.

Will CHORIOFIX be studied in clinical trials with MiMedx (MDXG)?

Yes. CHORIOFIX has been added to the CAMPAIGN prospective randomized controlled trial evaluating products versus standard of care for non-healing diabetic foot ulcers. According to the company, the trial will compare CHORIOFIX and EPIEFFECT against standard of care.

What clinical evidence supports CHORIOFIX effectiveness for wound care?

Evidence cited is early access anecdotal clinical observations highlighting handling and wound closure in some patients. According to the company, CHORIOFIX is now enrolled in an RCT (CAMPAIGN) to generate controlled clinical data.

What wounds is CHORIOFIX intended to treat, per MiMedx (MDXG)?

CHORIOFIX is intended as a barrier to provide a protective environment in acute and chronic wounds, including large deficits and deep, tunneling wounds. According to the company, its thicker composition suits challenging wound types.